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Abstract
Aims/hypothesis The determinants of cerebral complica-
tions of type 2 diabetes are unclear. The present study
aimed to identify metabolic and vascular factors that are
associated with impaired cognitive performance and abnor-
malities on brain MRI in patients with type 2 diabetes.
Methods The study included 122 patients and 56 controls.
Neuropsychological test scores were divided into five
cognitive domains and expressed as standardised z values.
Brain MRI scans were rated for white matter lesions
(WML), cortical and subcortical atrophy, and infarcts. Data
on glucose metabolism, vascular risk factors and micro- and
macrovascular disease were collected.
Results Patients with type 2 diabetes had more cortical (p<
0.001) and subcortical (p<0.01) atrophy and deep WML (p=
0.02) than the control group and their cognitive performance
was worse. In multivariate regression analyses within the type
2 diabetes group, hypertension (p<0.05) and a history of
vascular events (p<0.01) were associated with worse cogni-
tive performance, while statin use was associated (p<0.05)
with better performance. Retinopathy and brain infarcts on
MRI were associated with more severe cortical atrophy (both
p<0.01) and statin use with less atrophy (p<0.05). Insulin
level and brain infarcts were associated with more severe
WML and statin use with less severe WML (all p<0.05).
Conclusions/interpretation Type 2 diabetes is associated
with modest impairments in cognition, as well as atrophy
and vascular lesions on MRI. This ‘diabetic encephalopa-
thy’ is a multifactorial condition, for which atherosclerotic
(macroangiopathic) vascular disease is an important deter-
minant. Chronic hyperglycaemia, hyperinsulinaemia and
hypertension may play additional roles.
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Introduction
Diabetes mellitus is associated with slowly progressive
changes in the brain [1]. Neuropsychological studies show
that patients with type 2 diabetes mellitus have mild to
moderate impairments in attention and executive function-
ing, information processing speed and memory (for reviews
see [2, 3]). Patients with type 2 diabetes also show changes
on brain magnetic resonance imaging (MRI), such as
cortical and hippocampal atrophy [4, 5]. We have recently
shown that cognitive dysfunction in patients with type 2
diabetes was associated with white matter lesions (WML),
(silent) brain infarcts and to a lesser extent with atrophy [6].
The determinants of changes in cognition and abnormal-
ities on brain MRI of patients with type 2 diabetes are
uncertain [2]. Some studies report associations with
hypertension [3, 4, 7, 8], but this was not supported by
others [5, 9, 10]. Associations between impaired cognition
and chronic hyperglycaemia have also been noted [9].
Studies on other diabetic complications may provide leads
for potentially relevant determinants. Complications like
nephropathy, retinopathy and neuropathy are thought to be
due to hyperglycaemia-induced microangiopathy [11, 12],
with additional involvement of hypertension and macro-
vascular disease [13–15]. Since atherosclerosis and hyper-
tension are established risk factors for age-related cognitive
decline and brain MRI changes in the general population
[16–19], we hypothesised that the combined effects of
atherosclerotic macrovascular disease, chronic hyperglycae-
mia and hypertension are involved in the development of
cognitive impairments in patients with type 2 diabetes.
The aim of the present study was to identify possible
metabolic and vascular determinants of cognitive dysfunc-
tion and changes on brain MRI in patients with type 2
diabetes. Given the uncertainty about these determinants, an
exploratory design was chosen. A detailed neuropsycho-
logical examination and brain MRI were obtained from a
large cross-sectional sample of type 2 diabetes patients and
related to different measures of glucose metabolism,
vascular risk factors, microvascular complications and
macrovascular disease.
Methods
Participants The Utrecht Diabetic Encephalopathy Study
aims to identify determinants of cognitive impairment in
patients with diabetes [6]. Therefore, patients were not
selected for the presence or absence of diabetic complica-
tions, co-morbid conditions (e.g. hypertension) or exposure
to other risk factors (e.g. smoking). For inclusion patients
had to be 55 to 80 years of age, functionally independent
and speakers of Dutch, with a minimal diabetes duration of
1 year. Exclusion criteria for all participants were: a
psychiatric or neurological disorder that could influence
cognitive functioning; a history of alcohol or substance
abuse and dementia; and, for the control group, a fasting
blood glucose ≥7.0 mmol/l [20]. Participants with a history
of stroke who were still fully functionally independent were
classified as eligible. To increase statistical power for
within-group analyses in the type 2 diabetes group, twice
as many patients as controls were enrolled.
Overall, 122 patients with type 2 diabetes (age 56–
80 years) and 56 controls (age 57–78 years) were included
in the present study. Patients were recruited through their
general practitioners; controls were spouses or acquain-
tances of the patients. Groups were comparable for age, sex
and educational level. The study was approved by the local
medical ethics committee and each participant signed an
informed consent form. All participants underwent a 2 day
protocol,whichincludedbrainMRI,aneurologicalandneuro-
psychological examination, retinal photography and ultraso-
nography of the carotid arteries. Fasting blood and urine
samples were collected and blood pressure was recorded. In
one control person and two type 2 diabetes patients it was not
possible to perform the neuropsychological examination.
Similarly, MRIs could not be obtained in five controls and
nine type 2 diabetes patients, mostly due to MRI contra-
indications (claustrophobia, pacemaker).
Neuropsychological examination The neuropsychological
examination tapped the major cognitive domains in verbal
and non-verbal ways. Eleven tasks were administered in a
fixed order, taking about 90 min to complete. These tasks
were divided into five cognitive domains, as described
previously [6]: (1) attention and executive functioning; (2)
information processing speed; (3) memory; (4) abstract
reasoning; and (5) visuoconstruction. For analysis the test
scores were standardised into z scores for each of the five
domains, based on the means of the whole group. The mean
performance from each participant across the domains is
expressed as the composite cognitive z score.
Premorbid IQ was assessed with the Dutch version of the
National Adult Reading Test. To control for possible effects
of mood disturbances or affective disorders a Beck
depression inventory [21] was performed.
Brain MRI The MRI investigation (1.5 T; Philips Medical
Systems, Best, the Netherlands) consisted of an axial T1-
weighted and an axial T2 and T2 fluid-attenuating inverse
recovery (FLAIR) scan (TR/TE/TI: 6000/100/2000, field of
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WML were rated according to the Scheltens scale [22]
with slight modifications [6]. Periventricular WML
(PWML) were rated on a severity scale (0–2) at the frontal
and occipital horns and the body of the lateral ventricle on
both sides (sum score 0–12). For the rating of deep
(subcortical) WML (DWML) the brain was divided into
six regions: frontal, parietal, occipital, temporal, basal
ganglia and infra-tentorial. Per region the size and number
of WML were rated on a scale ranging from 0 to 6. The
total score thus ranged from 0 to 36.
Cortical atrophy was evaluated by the frontal interhemi-
spheric fissure ratio and the Sylvian fissure ratio [23].
Subcortical atrophy was evaluated by the bifrontal ratio and
by the bicaudate ratio [23]. These ratios were converted to z
scores: a cortical atrophy z score (mean of z frontal fissure
ratio and z Sylvian fissure ratio) and a subcortical atrophy z
score (mean of z bicaudate ratio and z bifrontal ratio).
All MRI scans were rated by two investigators (S. M.
Manschot and G. J. Biessels) blinded for presence or
absence of diabetes or other characteristics. In case of
disagreement of more than 1 point on the WML scales in a
particular region or more than 5 mm (actual size) on any of
the atrophy measurements (2 mm for fissure widths), a
consensus reading was held (0% of PWML, 4% of DWML
and 4% of atrophy ratio readings were thus affected). In all
other cases the readings of both raters were averaged.
Diabetes characteristics and glucose metabolism As t a n -
dardised questionnaire addressed medical history, medication
use, diabetes duration and the life-time occurrence of severe
hypoglycaemic episodes (defined as episode of hypoglycae-
mia severe enough to require the assistance of another person,
hospitalisation or emergency room visit). BMI was calculated
as weight divided by height square.
Blood was drawn by venepuncture to assess HbA1c,
fasting glucose and insulin levels. Insulin resistance was
estimated with the homeostasis model assessment of insulin
resistance (HOMA-IR). The HOMA-IR is calculated as
fasting glucose (mmol/l) × fasting insulin (mU/l)/22.5 [24].
Because insulin was expressed in pmol/l we used the
formula fasting glucose (mmol/l) × fasting insulin (pmol/l)/
(22.5×6.945) [24].
Vascular risk factors Blood pressure was measured at home
at nine fixed time points during the day with an automatic
blood pressure machine (705CP; Omron, Mannheim,
Germany). These measurements were averaged. In the
primary analysis hypertension was defined as a mean
systolic blood pressure >160 mmHg or a mean diastolic
pressure >95 mmHg or the use of antihypertensive
medication. In a second analysis cut-off values for systolic
and diastolic blood pressure of 140 and 90 mmHg were
used.
Smoking habits were classified as ‘current’ and ‘past or
never’. Total cholesterol, HDL-cholesterol, LDL-cholesterol
and triacylglycerol were assessed in a fasting venous blood
sample.
Microvascular disease Following mydriasis with phenyleph-
rine and tropicamide, single-field photographs were taken of
both eyes with a 50-degree retinal camera (Zeiss FF 450, Carl
ZeissB.V.,Sliedrecht,theNetherlands),centredonthemacula.
Retinopathy was rated on slides, according to the diabetic
retinopathy severity scale (grades 1–7) as used in the
Wisconsin Epidemiologic Study of Diabetic Retinopathy
[25]. Photocoagulated eyes were rated at grade 5 or higher
(severe non-proliferative diabetic retinopathy). Ratings were
performed by two investigators, blinded to patient character-
istics. In case of disagreement (2%), a third investigator was
involved and a consensus was made. Retinopathy was
defined as a grade of 1.5 or higher.
Neuropathy was rated with the Toronto Clinical Neu-
ropathy Scoring System [26], with a slight modification. A
sensory test for temperature was not performed, so that the
maximum score was 18 points (severe polyneuropathy)
instead of 19. A score of 0–5 indicated no neuropathy, 6–
8 indicated mild neuropathy, 9–11 moderate neuropathy
and ≥12 severe neuropathy. Neuropathy was defined as a
score of ≥6.
Urinewascollectedovernight.Albuminuriawasdefinedas
microalbuminuria (albumin 0.03–0.25 g/l) or macroalbumin-
uria (albumin 0.25 g/l or positive protein dipstick test).
Macrovascular disease Several composite measures of
macrovascular disease were defined. ‘Any peripheral
arterial disease’ was defined as current complaints of
intermittent claudication (assessed with the Rose question-
naire [27]) or a history of surgery or endovascular treatment
for arterial disease of the legs or the abdominal aorta.
‘Ischaemic heart disease’ was defined as a history of
myocardial infarction or surgery or endovascular treatment
for coronary artery disease. ‘Any vascular event’ was
defined as a history of myocardial infarction or stroke, or
a history of operative or endovascular treatment for
coronary, carotid or peripheral (legs, abdominal aorta)
artery disease.
Brain infarcts were rated on brain MRI, by location
(cortical and subcortical), size (lacunar [<1.5 cm] or large)
and number. A lesion was considered an infarct if it was
hypo-intense on T1 and FLAIR images and if its appear-
ance was unlike a perivascular space.
Carotid intima-media thickness (CIMT) was measured in
both common carotid arteries as described previously [28]
with an ATL Ultramark 9 (Advanced Technology Labora-
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array transducer. Scanning was performed at three different
longitudinal projections (anterior-oblique, lateral and
posterior-oblique). The CIMT was measured in a 1 cm
section proximal to the beginning of the dilatation of the
carotid bulb in all three projections, in both carotid arteries.
CIMT was calculated as the average of these six measure-
ments. CIMT readings were not available in six type 2
diabetes patients and one person in the control group.
Statistical analysis The differences between patients and
the control group were examined with t test for means,
Mann–Whitney U was used for non-parametric data and χ
2
test for proportions. In the text and tables, data are shown as
mean ± SD or proportions, unless stated otherwise.
Within the type 2 diabetes population, cognition (five
domains) and brain MRI findings (cortical and subcortical
atrophy z scores, PWML, DMWL and infarcts) were related
to the different measures of glucose, insulin and lipid
metabolism, and to microvascular complications and
macrovascular disease by linear or logistic regression
analyses, adjusting for age, sex and estimated IQ. In order
to limit the number of analyses the ‘composite cognitive z
score’ was used as the primary cognitive outcome measure
in the regression analyses. For significant associations, post
hoc tests were performed per domain. Secondary analyses
were performed with information processing speed, the
domain most markedly affected by type 2 diabetes. The
results were essentially the same as for the composite
cognitive z score (data not shown).
In the regression analyses, B values >0 indicate that a
variable is associated with more severe MR abnormalities;
for cognition B values <0 indicate that a variable is
associated with more pronounced performance impair-
ments. For the between and within-group analyses, p<
0.05 was considered statistically significant. All variables
that reached a significance level of p≤0.1 in the adjusted
univariate risk factor analyses were included in a multivar-
iate model that also included age, sex and estimated IQ.
Results
Participant characteristics The age, sex, level of educa-
tion and estimated IQ in the groups were comparable
(Table 1).
Detailed neuropsychological and MRI data have been
reported previously [6]. In short, performance of patients
with type 2 diabetes was worse than that of the control
group across all five cognitive domains, with statistically
significant differences on attention and executive function-
ing (difference mean z scores 0.23 [95% CI 0.03, 0.43]; p=
0.02), information processing speed (0.40 [0.17, 0.63]; p=
0.001) and memory (0.20 [0.05, 0.36]; p=0.01). Patients
with type 2 diabetes had more pronounced cortical atrophy
(difference mean z scores 0.62 [95% CI 0.33, 0.91]; p<
0.001) and subcortical atrophy (0.38 [0.07, 0.68]; p=0.01).
They also had more severe DWML (controls, median
[range]: 5 [0, 18]; type 2 diabetes: 7 [0.5, 27.5]; p=0.02),
but PWML severity in the two groups was similar (control:
6[ 4, 10]; type 2 diabetes: 6 [3, 12]; p=0.13). Patients with
type 2 diabetes also had more (silent) cerebral infarcts than
controls (type 2 diabetes 22/113, control 4/54; p=0.06).
Glucose metabolism HbA1c, fasting glucose and insulin
levels were higher (all p<0.01) in patients with type 2 diabetes
than in the control group. BMI was similar in both groups.
Only a small proportion (6%) of type 2 diabetes patients had
ever experienced a severe hypoglycaemic event (Table 1).
In the regression analyses within the type 2 diabetes
group, HbA1c levels were significantly related to cognition
(composite z score: B [per % HbA1c]: −0.07 [−0.14, 0] p=
0.047; post hoc per domain: information processing speed:
B [per % HbA1c]: −0.15 [95% CI: −0.27, −0.2], p=0.02;
abstract reasoning: B: −0.15 [−0.29, −0.01], p=0.04).
Elevated fasting insulin levels and HOMA-IR were related
Table 1 Participant characteristics
Characteristic Type 2 diabetes
group
Control group
Participants (n) 122 56
Sex (male/female) 62/60 25/31
Age (years) 66.0±5.8 65.1±5.2
Level of education (1–7)
a 4( 3 –5) 4 (3–5)
Estimated premorbid IQ 99±15 101±14
Diabetes duration (years)
b 8.7±6.1
Diabetes treatment (%)
Diet 10
Oral medication alone 61
Insulin
b 29
HbA1c (%)
b 6.9±1.2**
,d 5.5±0.3
Fasting glucose levels (mmol/l)
b 8.6±2.9** 5.5±0.6
Fasting insulin levels (pmol/l)
b,c 120±110**
,e
(n=82)
76±50
(n=54)
HOMA-IR
b,c 6.6±6.4**
,f 2.6±1.8
BMI (kg/m
2)
b 28.1±4.4 27.3±5.3
Data are given as number or percentage (as indicated), mean ± SD or
ranges
**p<0.01 for type 2 diabetes vs control group
aLevel of education was expressed in seven categories [49]
bEntered as explanatory variable in the regression analyses within the
type 2 diabetes group
cOnly from participants who were not treated with insulin and did not
have antibodies against insulin
Statistically significant associations within the type 2 diabetes
group: with composite cognitive z scores—
dp<0.05; with MRI
abnormalities—
ep<0.01,
fp<0.05
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0.14 [0.04, 0.26], p=0.009; B [HOMA-IR]: 0.21 [0.04,
0.39], p=0.02).
Vascular risk factors Table 2 shows that patients with type
2 diabetes had higher systolic blood pressure (p<0.01) and
pulse pressure (p<0.05) than controls. They also had
hypertension more often (p<0.01). Total cholesterol was
lower in the type 2 diabetes group (p<0.01), but the
proportion of individuals taking lipid-lowering drugs was
higher in that group (p<0.01). There were no statistically
significant differences between type 2 diabetic patients and
the control group in the proportion of participants who
smoked or had dyslipidaemia (Table 2).
In the regression analyses within the type 2 diabetes
group there were no statistically significant associations
with the composite cognitive z score. Non-significant trends
(p≤0.10) were observed for associations between both
hypertension and current smoking and impaired cognitive
performance (hypertension B: −0.19 [−0.38, 0], p=0.053;
smoking B: −0.21 [−0.43, 0], p=0.051), and between the
use of lipid-lowering drugs and better performance (B: 0.15
[−0.03, 0.32], p=0.10). Reanalysis with cut-off values for
hypertension of 140/90 mmHg made the association with
the composite cognitive z score less strong. Mean arterial
pressure was associated with more severe PWML (B [per
10 mmHg]: 0.28 [0.03, 0.53], p=0.03). The use of lipid-
lowering drugs (statins in all but one patient) was
associated with less severe MRI abnormalities (PWML:
B: −0.68 [−1.25, −0.12], p=0.02; cortical atrophy: B: −0.36
[−0.69, −0.03], p=0.03). These effects were not affected by
additional adjustment for the actual cholesterol levels
(Table 2).
Microvascular disease In 20 patients with type 2 diabetes
and 8 control individuals it was not possible to perform
retinal photographs. Mostly due to logistical reasons,
overnight urine samples could not be obtained from 21
diabetic patients and 13 controls. Patients with type 2
diabetes had more retinopathy and neuropathy than the
control group (both p<0.01). Although albuminuria was
more common in the type 2 diabetic than in the control
group, this difference was not statistically significant
(Table 3).
In the regression analyses within the type 2 diabetes
group, there were no statistically significant associations
with the composite cognitive z score. Retinopathy was
associated with more pronounced cortical atrophy (B: 0.48
[0.11, 0.85], p=0.01) (Table 3).
Macrovascular disease Patients with type 2 diabetes were
more likely to have had intermittent claudication (p<0.01)
or a history of ischaemic heart disease (p<0.01). There was
no difference between the two groups in the CIMT
(Table 4).
In the regression analyses within the type 2 diabetes
group, a history of ‘any vascular event’ and the presence of
brain infarcts on MRI were associated with an impaired
composite cognitive z score as follows: (1) vascular event:
composite z score B: −0.25 (−0.44, −0.05), p=0.01; post
hoc per domain: information processing speed B: −0.46
(−0.80, −0.12), p=0.008; and memory B: −0.23 (−0.41,
−0.06), p=0.01; (2) infarct on MRI: composite z score B:
Table 2 Vascular risk factors
Characteristic Type 2 diabetes
group (n=122)
Control group
(n=56)
Mean arterial pressure (mmHg)
a 103±11*
,b 98±10
Pulse pressure (mmHg)
a 65±15* 59±16
Hypertension (%)
a 73** 34
Antihypertensive drugs (%) 70** 32
Current smoking (%)
a 22 14
Total cholesterol (mmol/l)
a 5.0±0.9** 5.8±1.1
HDL-cholesterol (mmol/l)
a 4.3±1.2 4.4±1.5
Triacylglycerol (mmol/l)
a 1.9±1.0 1.6±1.1
Lipid-lowering drugs (%)
a 54**
,c 21
Data are given as percentage or mean ± SD
*p<0.05, **p<0.01 for type 2 diabetes vs control group
aEntered as explanatory variable in the regression analyses within the
type 2 diabetes group
bp<0.05 for association with more severe MRI abnormalities
cp<0.05 for reverse association
Table 3 Microvascular disease
Characteristic Type 2 diabetes
group (n=122)
Control group
(n=56)
Retinopathy (diabetes
n=112; control n=48)
a
37 (33)**
,b 1 (2)
Background 33 1
Severe non-proliferative 4
Neuropathy
a 47 (39)** 7 (13)
Mild neuropathy 25 7
Moderate neuropathy 18 0
Severe neuropathy 4 0
Albuminuria (diabetes
n=101; control n=43)
a
16 (16) 3 (7)
Microalbuminuria 9 3
Macroalbuminuria 7 0
Any microvascular disease
a,c 72 (59)** 11 (20)
Data are given as values (percentage)
**p<0.01 for type 2 diabetes vs control group
aEntered as explanatory variable in the regression analyses within the
type 2 diabetes group
bp<0.05 for association with MRI abnormalities
cIncludes all patients with albuminuria, neuropathy or retinopathy
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information processing speed B: −0.77 (−1.14, −0.39), p<
0.001; and abstract reasoning B: −0.41 (−0.82, 0.01), p=
0.06. A history of ‘any vascular event’ was also associated
with more pronounced DWML (B: 2.0 [0, 4.1], p=0.05)
and with an increased occurrence of infarcts on MRI (odds
ratio: 2.9 [1.1, 7.9], p=0.04). Patients with a (silent) infarct
on MRI tended to have more pronounced PWML (B: 0.7
[0, 1.4], p=0.06) and cortical atrophy (B: 0.51 [0.10, 0.92],
p=0.02) relative to type 2 diabetes patients without infarcts
on MRI (Table 4).
Exclusionofpatientswithahistoryofstrokeattenuatedthe
association between ‘any vascular event’ and the cognitive z
score, but not that between ‘any vascular event’ and DWML.
Multivariate analysis For the majority of risk factors the
values of the standardised regression coefficients ß were
similar in the single risk factor and multivariate models,
indicating that interaction between factors was limited.
Values for ß for individual factors varied between 0.15 and
0.30, indicative of modest associations (Table 5).
In the multivariate model, hypertension and a history of
vascular events were associated with worse cognitive
performance and statin use with better performance.
Retinopathy and brain infarction on MRI were associated
with more severe cortical atrophy and statin use with less
atrophy. A higher insulin level was associated with more
DWML, brain infarction on MRI with more PWML and
statin use with less PWML. Overall, macrovascular disease
(history of macrovascular events or infarct on MRI) were
most consistently associated with the different outcome
measures (Table 5).
Discussion
Patients with type 2 diabetes had more cortical and
subcortical atrophy and more DWML than control partic-
ipants and their overall performance in the five cognitive
domains was worse. As expected, patients with type 2
diabetes had more microvascular complications, more
macrovascular (atherosclerotic) disease and more hyperten-
sion than the control group. In multivariate regression
analyses within the type 2 diabetes group, hypertension and
a history of vascular events were associated with worse
cognitive performance, while statin use was associated with
better performance. Retinopathy and brain infarcts on MRI
were associated with more severe cortical atrophy and statin
use with less atrophy. Insulin level and brain infarcts were
associated with more severe WML and statin use with less
severe WML.
Cognitive function in patients with type 2 diabetes has
been studied extensively (for reviews see [2, 3]). Perfor-
mance in the domains verbal memory and information
processing speed, and probably also executive functioning
and non-verbal memory, is moderately impaired. Our
results are in keeping with these findings. Thus far,
relatively few studies have specifically addressed brain
MRI abnormalities in patients with type 2 diabetes. In
agreement with our observations, modest cortical and
subcortical atrophy and symptomatic or asymptomatic
infarcts have been found more often in type 2 diabetes
patients than in control individuals [4, 5, 29]. Results of
previous studies on the association between type 2 diabetes
and WMLs are less consistent [30]. This might be due to
the study populations involved and the use of relatively
insensitive WML rating scales [30].
Chronic hyperglycaemia might be a determinant of
cerebral changes in patients with type 2 diabetes. In the
present study, HbA1c levels were related to the composite
cognitive z score, but only in de univariate analysis.
Moreover, retinopathy, which is generally considered to
be a consequence of chronic exposure to hyperglycaemia
[11], was related to cortical atrophy. Previous studies on
cognition in patients with type 2 diabetes have also reported
an association with HbA1c levels [2, 9, 31]. The relation
Table 4 Macrovascular disease
Characteristic Type 2 diabetes
group (n=122)
Control group
(n=56)
Any peripheral arterial
disease
a
18 (15)** 0
Claudicatio
intermittens
14 (11)** 0
Vascular surgery
femoral artery
4 (3) 0
Vascular surgery
(AAA)
3 (3) 0
Ischaemic heart
disease
a
23 (19)**
,b 2 (4)
Myocardial infarction 15 (12)* 1 (2)
CABG 13 (11)* 1 (2)
Brain infarct on MRI
a 22 (20)*
,b,c 4 (8)
History of brain
infarct
a
7 (6) 2 (4)
Carotid surgery
a 2 (2) 1 (2)
Any vascular event
a 33 (27)**
,b,c 4 (7)
CIMT
a 0.093±0.018 0.092±0.023
Data are given as value (percentage) or mean ± SD
AAA,abdominalaorticaneurysm;CABG,coronaryarterybypassgrafting
*p<0.05, **p<0.01 for type 2 diabetes vs control group
aEntered as explanatory variable in the regression analyses within the
type 2 diabetes group
Statistically significant associations: with MRI abnormalities
bp<0.05;
with impaired cognition
cp<0.05
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however, inconsistent [31, 32]. No previous studies have
provided detailed data on the association between glycae-
mic control and MRI changes in type 2 diabetes. Studies in
type 1 diabetes mellitus, however, have shown an associ-
ation between diabetic retinopathy (as a proxy of chronic
hyperglycaemia) and both brain atrophy [33, 34]a n d
cognitive functioning [35]. There are no previous studies
on the relation between insulin levels and cerebral
complications in type 2 diabetes. The association with
WML severity, observed by us in the present study, is of
particular interest in the light of recent studies in the general
population, which link insulin to vascular abnormalities and
degenerative changes in the brain [36, 37].
Previous studies in the general population indicate that
risk factors for vascular disease, such as hypertension,
dyslipidaemia, increased BMI and smoking, are associated
with an increased risk of cognitive decline and dementia
and with brain MRI changes, including WML (e.g. [38–
41]). Previous studies on the modulating effect of hyper-
tension on cognitive function in type 2 diabetes show
conflicting results [7, 9, 42, 43]. In the present study,
hypertension was related with impaired cognitive perfor-
mance and mean arterial pressure with PWML severity. To
Table 5 Multivariate risk factor analyses within the type 2 diabetes group
Single factors β (95% CI) Full model β (95% CI) Final model β (95% CI)
Cognition
Age −0.30 (−0.44, −0.16)*** −0.29 (−0.43, −0.14)***
Sex −0.12 (−0.24, 0.02)
Estimated IQ 0.65 (0.50, 0.79)*** 0.65 (0.50, 0.80)***
HbA1c −0.14 (−0.28, −0.002)* −0.11 (−0.25, 0.02)
Hypertension −0.14 (−0.26, 0.002) −0.12 (−0.26, 0.01) −0.14 (−0.27, −0.001)*
Current smoking −0.14 (−0.29, 0.001) −0.15 (−0.29, −0.02)* −0.14 (−0.27, 0.001)
Lipid-lowering drugs 0.12 (−0.02, 0.26) 0.17 (0.03, 0.31)* 0.17 (0.03, 0.31)*
Any vascular event −0.18 (−0.32, −0.03)* −0.18 (−0.32, −0.03)* −0.19 (−0.34, −0.05)**
Brain infarct on MRI
a −0.18 (−0.32, −0.04)*
Cortical atrophy
Sex −0.005 (−0.23, 0.22)
Age 0.35 (0.18, 0.52)*** 0.34 (0.18, 0.51)***
Estimated IQ −0.07 (−0.24, 0.10)
Lipid-lowering drugs −0.20 (−0.37, −0.02)* −0.19 (−0.36, −0.03)* −0.18 (−0.35, −0.02)*
Retinopathy 0.24 (0.05, 0.43)* 0.21 (0.04, 0.39)* 0.22 (0.06, 0.39)**
Brain infarct on MRI 0.22 (0.04, 0.39)* 0.23 (0.06, 0.40)** 0.23 (0.06, 0.40)**
DWML
Sex 0.13 (−0.05, 0.30)
Age 0.20 (0.02, 0.35)* 0.22 (0.04, 0.39)*
Estimated IQ −0.14 (−0.31, 0.04)
Insulin level 0.29 (0.08, 0.51)** 0.26 (0.04, 0.47)* 0.24 (0.03, 0.45)*
Any vascular event 0.19 (−0.002, 0.37) 0.15 (−0.03, 0.34)
PWML
Sex 0.16 (−0.02, 0.34) 0.16 (−0.02, 0.34)
Age 0.25 (0.07, 0.43)** 0.24 (0.07, 0.42)**
Estimated IQ −0.12 (−0.30, 0.06)
Mean arterial pressure 0.20 (0.02, 0.38)* 0.15 (−0.03, 0.33) 0.17 (−0.004, 0.35)
Lipid-lowering drugs −0.22 (−0.35, −0.001)* −0.20 (−0.38, −0.02)* −0.18 (−0.35, 0.001)*
Brain infarct on MRI 0.17 (−0.006, 0.35) 0.18 (0.01, 0.36)* 0.18 (0.009, 0.36)*
β is the standardised regression coefficient B. The first column contains the values of β for all variables that reached a significance level of a least
p=0.10 in the univariate risk factor analyses within the type 2 diabetes patient group, adjusted for age, sex and estimated IQ. These variables were
included in a multivariate model that also included age, sex and estimated IQ (second column, full model). The final model (third column) is
based on backward elimination of non-significant factors. This final model shows which variables that were related to the outcome measures in
the univariate model remained significantly associated with the outcome measures independently of the other factors in the full model
For cognition β values <0 indicate that a variable is associated with more pronounced performance impairments; for MRI β values >0 indicate that
a variable is associated with more severe MRI abnormalities
*p<0.05
**p<0.01
***p<0.001
aBecause ‘infarct on MRI’ and ‘history of any vascular event’ were interrelated in the univariate analyses (see Macrovascular disease section) only
‘history of any vascular event’ was entered in the multivariate model
2394 Diabetologia (2007) 50:2388–2397our knowledge, the relation between other vascular risk
factors and both cognition and brain MRI in patients with
type 2 diabetes has not been examined previously. The
reverse association between the use of statins and both
cognition and MRI findings is intriguing. Nevertheless, this
observation cannot be regarded as proof of a possible
treatment effect. It should be noted that the association
between statin use and both cognition and age-related brain
MRI changes in the general population is still being
debated [44]. The present findings will need to be
confirmed by further studies.
Macrovascular atherosclerotic disease appeared to be the
most consistent determinant of impaired cognition and
brain MRI abnormalities in the type 2 diabetes patients in
the present study. We have not found any previous studies
that presented detailed data on the relation between macro-
vascular disease and cerebral changes in people with type 2
diabetes. In the general population, however, several studies
have shown that macrovascular atherosclerotic disease is
associated with age-related cognitive impairment and
changes in brain MRI. In a large cross-sectional study, for
example, previous vascular events, presence of plaques in
the carotid arteries and presence of peripheral arterial
atherosclerotic disease were negatively associated with
cognitive performance [17]. In another study, the associa-
tion between the number of cardiovascular disease con-
ditions and cognitive impairment appeared to show a
‘dose–response’ relationship [18]. With regard to brain
MRI changes, a history of stroke or myocardial infarction
has been associated with the presence of WML [19] and
plaques in the carotid artery with PWML [16, 45].
The strength of our study is that we combined detailed data
on cognitive function and brain MRI with detailed data on
metabolic and vascular risk factor clusters, thus allowing an
accurate assessment of the relation between these factors.
Possible limitations include patient selection, the cross-
sectional design and the large number of explanatory variables
addressed. With regard to patient selection, we aimed to obtain
a representative sample of functionally independent patients
with type 2 diabetes from the general population. Although the
rather demanding testing protocol may have deterred patients
with relatively severe mental or physical limitations, the
prevalence of microvascular and macrovascular disease,
hypertension and smoking habits, as well as the level of
metaboliccontrolinourstudysampleiscomparablewiththose
found in other population-based studies in the Netherlands
[46–48]. To minimise the effects of lifestyle and socioeco-
nomic factors, control participants were recruited from the
direct environment of the type 2 diabetic patients. Conse-
quently, the prevalence of risk factors such as hypertension
and high BMI was higher than would be expected in the
general population in the Netherlands. If anything, this would
have decreased the differences in cognition and MRI ratings
between the groups. The cross-sectional design of our study
precludes inferences about causal relationships. Moreover, the
cognitive and imaging outcome measures were probably
influenced by a large number of factors, some of which are
specific to type 2 diabetes mellitus (e.g. chronic hyper-
glycaemia, diabetes treatment) and some not (e.g. age,
hypertension, atherosclerosis). Our exploratory analysis in-
cluded a large number of explanatory variables, which has
certain drawbacks. First, different explanatory variables might
be interrelated. The relatively small regression coefficients
and effect sizes affect the evaluation of these interrelations
and limit statistical power. This may also explain why some
of the variables that reached statistical significance in the
univariate analyses dropped out of the multivariate model.
Nevertheless, the multivariate analysis as presented in Table 5
does indicate which variables were the strongest independent
determinants of cognition and MRI abnormalities in the
model used. The second drawback is that the large number of
regression analyses can lead to type I errors. Nevertheless, we
feel that this first detailed study of cognition and brain MRI
in type 2 diabetes patients in relation to metabolic and
vascular risk factors does provide important leads that could
be further evaluated in future studies. Such studies should: (1)
preferably have a longitudinal design; (2) include assessment
of cognition and brain MRI in relation to chronic hyper-
glycaemia and atherosclerotic vascular disease; and (3) allow
the assessment of potential confounders (e.g. hypertension).
Type 2 diabetes is associated with modest impairments
in cognition, as well as with atrophy and vascular lesions
on MRI. This ‘diabetic encephalopathy’ is a multifactorial
condition, for which atherosclerotic (macroangiopathic)
vascular disease is an important determinant. Chronic
hyperglycaemia, hypertension and hyperinsulinaemia may
play additional roles.
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